TY  - JOUR
A1  - Jutzi, Peter
A1  - Karl, Alfons
A1  - Burschka, Christian
T1  - Synthese, Reaktionen und Struktur von Tricarbonyl(1R,1R',2,3,4,5-Tetraphenyl-1-Germacyclopentadien) Eisen-Komplexen
N2  - Die Tricarbonyl(germacy~lopentadien)eisen-Komplexe VI-X werden durch Umsetzung der Germacyclopentadiene I-V niit Fe(CO)\(_5\) dargestellt. In l,l-Dialkyl- und -Diaryl-l-gemiacyclopentadien-Komplexen kann die Ge-C( exo )-Bindung durch verschiedene Elementhaloge~de gespalten werden, wobei die I-Halogen-l-germacyclopentadien-Komplexe XII, XIII, XV-XVII gebildet werden. Eine Entkomplexierung des Komplexes XI tritt bei der Reaktion mit Me\(_3\)NO oder TiCl\(_4\) ein. Das Tricarbonyl(l-chlor-l-germacyclopentadien)eisen XII reagiert mit AgF, NaJ, NaOMe und LiAIH\(_4\) zu den Komplexen XIXXXII. Das German XXII kann mit CCl\(_4)\ in XII überführt werden. Die Tricarbonyleisen-Komplexe XI, XII, XVI, XVII und XIX reagieren photochemisch mit Trimethylphosphan zu den Dicarbonyl(trimethylphosphan)-Komplexen XXIII-XXVII. Die Kristallstruktur des Tricarbonyl(l-exo-fluor-1-endo-methyl-2,3,4,5-tetraphenyl-1-germacyclopentadien)eisen wird beschrieben.
N2  - The tricarbonyl(germacyclopentadiene)iron complexes VI-X are synthesized by the reaction of the germacyclopentadienes I-V with Fe(CO)\(_5\). In l,l-dialkyl- and -diaryi-l-germacyclopentadiene complexes the Ge-C(exo) bond can be split by different element halides, whereby the I-halo-l-germacyclopentadiene complexes XII. XIII. XV-XVII are formed. Decomplexation takes place by the reaction of complex XI with Me\(_3\)NO or TiCl\(_4\). Tricarbonyl(l-chloro-1-germacyclopentadiene)iron (XII) reacts with AgF. NaI. NaOMe and LiAIH\(_4\) to the complexes XIX-XXII. The germane XXII can be transferred to XII with CCl\(_4)\. The tricarbonyliron complexes XI. XII. XVI. XVII and XIX react photochemicaIly with trimethylphosphane to the dicarbonyl(trimethylphosphane) complexes XXIII-XXVll. The crystal structure of tricarbonyl(1-exo-fluoro-l-endo-methyl-2,3,4,5-tetraphenyl-l-germacyclopentadiene) iron is described.
KW  - Chemie
Y1  - 1981
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-46723
ER  - 
TY  - JOUR
A1  - Dumont, Martine
A1  - Weber-Lassalle, Nana
A1  - Joly-Beauparlant, Charles
A1  - Ernst, Corinna
A1  - Droit, Arnaud
A1  - Feng, Bing-Jian
A1  - Dubois, Stéphane
A1  - Collin-Deschesnes, Annie-Claude
A1  - Soucy, Penny
A1  - Vallée, Maxime
A1  - Fournier, Frédéric
A1  - Lemaçon, Audrey
A1  - Adank, Muriel A.
A1  - Allen, Jamie
A1  - Altmüller, Janine
A1  - Arnold, Norbert
A1  - Ausems, Margreet G. E. M.
A1  - Berutti, Riccardo
A1  - Bolla, Manjeet K.
A1  - Bull, Shelley
A1  - Carvalho, Sara
A1  - Cornelissen, Sten
A1  - Dufault, Michael R.
A1  - Dunning, Alison M.
A1  - Engel, Christoph
A1  - Gehrig, Andrea
A1  - Geurts-Giele, Willemina R. R.
A1  - Gieger, Christian
A1  - Green, Jessica
A1  - Hackmann, Karl
A1  - Helmy, Mohamed
A1  - Hentschel, Julia
A1  - Hogervorst, Frans B. L.
A1  - Hollestelle, Antoinette
A1  - Hooning, Maartje J.
A1  - Horváth, Judit
A1  - Ikram, M. Arfan
A1  - Kaulfuß, Silke
A1  - Keeman, Renske
A1  - Kuang, Da
A1  - Luccarini, Craig
A1  - Maier, Wolfgang
A1  - Martens, John W. M.
A1  - Niederacher, Dieter
A1  - Nürnberg, Peter
A1  - Ott, Claus-Eric
A1  - Peters, Annette
A1  - Pharoah, Paul D. P.
A1  - Ramirez, Alfredo
A1  - Ramser, Juliane
A1  - Riedel-Heller, Steffi
A1  - Schmidt, Gunnar
A1  - Shah, Mitul
A1  - Scherer, Martin
A1  - Stäbler, Antje
A1  - Strom, Tim M.
A1  - Sutter, Christian
A1  - Thiele, Holger
A1  - van Asperen, Christi J.
A1  - van der Kolk, Lizet
A1  - van der Luijt, Rob B.
A1  - Volk, Alexander E.
A1  - Wagner, Michael
A1  - Waisfisz, Quinten
A1  - Wang, Qin
A1  - Wang-Gohrke, Shan
A1  - Weber, Bernhard H. F.
A1  - Devilee, Peter
A1  - Tavtigian, Sean
A1  - Bader, Gary D.
A1  - Meindl, Alfons
A1  - Goldgar, David E.
A1  - Andrulis, Irene L.
A1  - Schmutzler, Rita K.
A1  - Easton, Douglas F.
A1  - Schmidt, Marjanka K.
A1  - Hahnen, Eric
A1  - Simard, Jacques
T1  - Uncovering the contribution of moderate-penetrance susceptibility genes to breast cancer by whole-exome sequencing and targeted enrichment sequencing of candidate genes in women of European ancestry
JF  - Cancers
N2  - Rare variants in at least 10 genes, including BRCA1, BRCA2, PALB2, ATM, and CHEK2, are associated with increased risk of breast cancer; however, these variants, in combination with common variants identified through genome-wide association studies, explain only a fraction of the familial aggregation of the disease. To identify further susceptibility genes, we performed a two-stage whole-exome sequencing study. In the discovery stage, samples from 1528 breast cancer cases enriched for breast cancer susceptibility and 3733 geographically matched unaffected controls were sequenced. Using five different filtering and gene prioritization strategies, 198 genes were selected for further validation. These genes, and a panel of 32 known or suspected breast cancer susceptibility genes, were assessed in a validation set of 6211 cases and 6019 controls for their association with risk of breast cancer overall, and by estrogen receptor (ER) disease subtypes, using gene burden tests applied to loss-of-function and rare missense variants. Twenty genes showed nominal evidence of association (p-value < 0.05) with either overall or subtype-specific breast cancer. Our study had the statistical power to detect susceptibility genes with effect sizes similar to ATM, CHEK2, and PALB2, however, it was underpowered to identify genes in which susceptibility variants are rarer or confer smaller effect sizes. Larger sample sizes would be required in order to identify such genes.
KW  - breast cancer
KW  - genetic susceptibility
KW  - whole-exome sequencing
KW  - moderate-penetrance genes
Y1  - 2022
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-281768
SN  - 2072-6694
VL  - 14
IS  - 14
ER  - 
TY  - JOUR
A1  - Weber-Lassalle, Nana
A1  - Hauke, Jan
A1  - Ramser, Juliane
A1  - Richters, Lisa
A1  - Groß, Eva
A1  - Blümcke, Britta
A1  - Gehrig, Andrea
A1  - Kahlert, Anne-Karin
A1  - Müller, Clemens R.
A1  - Hackmann, Karl
A1  - Honisch, Ellen
A1  - Weber-Lassalle, Konstantin
A1  - Niederacher, Dieter
A1  - Borde, Julika
A1  - Thiele, Holger
A1  - Ernst, Corinna
A1  - Altmüller, Janine
A1  - Neidhardt, Guido
A1  - Nürnberg, Peter
A1  - Klaschik, Kristina
A1  - Schroeder, Christopher
A1  - Platzer, Konrad
A1  - Volk, Alexander E.
A1  - Wang-Gohrke, Shan
A1  - Just, Walter
A1  - Auber, Bernd
A1  - Kubisch, Christian
A1  - Schmidt, Gunnar
A1  - Horvath, Judit
A1  - Wappenschmidt, Barbara
A1  - Engel, Christoph
A1  - Arnold, Norbert
A1  - Dworniczak, Bernd
A1  - Rhiem, Kerstin
A1  - Meindl, Alfons
A1  - Schmutzler, Rita K.
A1  - Hahnen, Eric
T1  - BRIP1 loss-of-function mutations confer high risk for familial ovarian cancer, but not familial breast cancer
JF  - Breast Cancer Research
N2  - Background
Germline mutations in the BRIP1 gene have been described as conferring a moderate risk for ovarian cancer (OC), while the role of BRIP1 in breast cancer (BC) pathogenesis remains controversial.

Methods
To assess the role of deleterious BRIP1 germline mutations in BC/OC predisposition, 6341 well-characterized index patients with BC, 706 index patients with OC, and 2189 geographically matched female controls were screened for loss-of-function (LoF) mutations and potentially damaging missense variants. All index patients met the inclusion criteria of the German Consortium for Hereditary Breast and Ovarian Cancer for germline testing and tested negative for pathogenic BRCA1/2 variants.

Results
BRIP1 LoF mutations confer a high OC risk in familial index patients (odds ratio (OR) = 20.97, 95% confidence interval (CI) = 12.02–36.57, P < 0.0001) and in the subgroup of index patients with late-onset OC (OR = 29.91, 95% CI = 14.99–59.66, P < 0.0001). No significant association of BRIP1 LoF mutations with familial BC was observed (OR = 1.81 95% CI = 1.00–3.30, P = 0.0623). In the subgroup of familial BC index patients without a family history of OC there was also no apparent association (OR = 1.42, 95% CI = 0.70–2.90, P = 0.3030). In 1027 familial BC index patients with a family history of OC, the BRIP1 mutation prevalence was significantly higher than that observed in controls (OR = 3.59, 95% CI = 1.43–9.01; P = 0.0168). Based on the negative association between BRIP1 LoF mutations and familial BC in the absence of an OC family history, we conclude that the elevated mutation prevalence in the latter cohort was driven by the occurrence of OC in these families. Compared with controls, predicted damaging rare missense variants were significantly more prevalent in OC (P = 0.0014) but not in BC (P = 0.0693) patients.

Conclusions
To avoid ambiguous results, studies aimed at assessing the impact of candidate predisposition gene mutations on BC risk might differentiate between BC index patients with an OC family history and those without. In familial cases, we suggest that BRIP1 is a high-risk gene for late-onset OC but not a BC predisposition gene, though minor effects cannot be excluded.
KW  - breast cancer
KW  - ovarian cancer
KW  - BRIP1 gene
KW  - germline mutations
Y1  - 2018
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-233433
VL  - 20
ER  - 
TY  - JOUR
A1  - Hauke, Jan
A1  - Horvath, Judit
A1  - Groß, Eva
A1  - Gehrig, Andrea
A1  - Honisch, Ellen
A1  - Hackmann, Karl
A1  - Schmidt, Gunnar
A1  - Arnold, Norbert
A1  - Faust, Ulrike
A1  - Sutter, Christian
A1  - Hentschel, Julia
A1  - Wang-Gohrke, Shan
A1  - Smogavec, Mateja
A1  - Weber, Bernhard H. F.
A1  - Weber-Lassalle, Nana
A1  - Weber-Lassalle, Konstantin
A1  - Borde, Julika
A1  - Ernst, Corinna
A1  - Altmüller, Janine
A1  - Volk, Alexander E.
A1  - Thiele, Holger
A1  - Hübbel, Verena
A1  - Nürnberg, Peter
A1  - Keupp, Katharina
A1  - Versmold, Beatrix
A1  - Pohl, Esther
A1  - Kubisch, Christian
A1  - Grill, Sabine
A1  - Paul, Victoria
A1  - Herold, Natalie
A1  - Lichey, Nadine
A1  - Rhiem, Kerstin
A1  - Ditsch, Nina
A1  - Ruckert, Christian
A1  - Wappenschmidt, Barbara
A1  - Auber, Bernd
A1  - Rump, Andreas
A1  - Niederacher, Dieter
A1  - Haaf, Thomas
A1  - Ramser, Juliane
A1  - Dworniczak, Bernd
A1  - Engel, Christoph
A1  - Meindl, Alfons
A1  - Schmutzler, Rita K.
A1  - Hahnen, Eric
T1  - Gene panel testing of 5589 BRCA1/2-negative index patients with breast cancer in a routine diagnostic setting: results of the German Consortium for Hereditary Breast and Ovarian Cancer
JF  - Cancer Medicine
N2  - The prevalence of germ line mutations in non-BRCA1/2 genes associated with hereditary breast cancer (BC) is low, and the role of some of these genes in BC predisposition and pathogenesis is conflicting. In this study, 5589 consecutive BC index patients negative for pathogenic BRCA1/2 mutations and 2189 female controls were screened for germ line mutations in eight cancer predisposition genes (ATM, CDH1, CHEK2, NBN, PALB2, RAD51C, RAD51D, and TP53). All patients met the inclusion criteria of the German Consortium for Hereditary Breast and Ovarian Cancer for germ line testing. The highest mutation prevalence was observed in the CHEK2 gene (2.5%), followed by ATM (1.5%) and PALB2 (1.2%). The mutation prevalence in each of the remaining genes was 0.3% or lower. Using Exome Aggregation Consortium control data, we confirm significant associations of heterozygous germ line mutations with BC for ATM (OR: 3.63, 95%CI: 2.67–4.94), CDH1 (OR: 17.04, 95%CI: 3.54–82), CHEK2 (OR: 2.93, 95%CI: 2.29–3.75), PALB2 (OR: 9.53, 95%CI: 6.25–14.51), and TP53 (OR: 7.30, 95%CI: 1.22–43.68). NBN germ line mutations were not significantly associated with BC risk (OR:1.39, 95%CI: 0.73–2.64). Due to their low mutation prevalence, the RAD51C and RAD51D genes require further investigation. Compared with control datasets, predicted damaging rare missense variants were significantly more prevalent in CHEK2 and TP53 in BC index patients. Compared with the overall sample, only TP53 mutation carriers show a significantly younger age at first BC diagnosis. We demonstrate a significant association of deleterious variants in the CHEK2, PALB2, and TP53 genes with bilateral BC. Both, ATM and CHEK2, were negatively associated with triple-negative breast cancer (TNBC) and estrogen receptor (ER)-negative tumor phenotypes. A particularly high CHEK2 mutation prevalence (5.2%) was observed in patients with human epidermal growth factor receptor 2 (HER2)-positive tumors.
KW  - breast cancer predisposition
KW  - hereditary breast cancer
Y1  - 2018
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-227902
ER  -